Eloralintide Guides

What Is Eloralintide? The Selective Amylin Agonist Explained

Eloralintide (LY3841136) is Eli Lilly’s once-weekly selective amylin receptor agonist, in phase 3 for obesity. How it works, its half-life, trial results and status.

Eloralintide Clinical Trial Results: Phase 1, Phase 2 and Phase 3

Every eloralintide trial result to date: up to 20.1% weight loss at 48 weeks in phase 2, the EloraTZP combination at 23.3%, and the six ENLIGHTEN phase 3 trials due from 2028.

Eloralintide Dosage: The Doses Used in Clinical Trials

The eloralintide doses tested in trials: 0.04 to 12 mg in phase 1, 1, 3, 6 and 9 mg once weekly in phase 2, escalation schedules and results by dose. Trial data only, not dosing advice.

Eloralintide vs Retatrutide: How the Two Lilly Drugs Compare

Eloralintide vs retatrutide side by side: amylin agonist vs GIP/GLP-1/glucagon triple agonist, 20.1% vs 24.2% weight loss at 48 weeks in phase 2, side effects and approval timing.

Eloralintide vs Tirzepatide, and the EloraTZP Combination

Eloralintide vs tirzepatide (Zepbound, Mounjaro): amylin vs GIP/GLP-1, 20.1% at 48 weeks vs 20.9% at 72 weeks, and EloraTZP, the combination that reached 23.3% in type 2 diabetes.

Eloralintide vs Cagrilintide: Two Amylin Analogues Compared

Eloralintide vs cagrilintide: Lilly’s selective amylin agonist vs Novo Nordisk’s non-selective one. Receptor selectivity, half-life, 20.1% vs 10.8% weight loss, CagriSema and amycretin.

Eloralintide Side Effects: What the Trials Reported

Eloralintide side effects from the phase 1 and phase 2 trials: nausea 11% to 64% by dose, fatigue, vomiting, heart rate and mood events, with every figure linked to its source.

Eloralintide Price: Research Vial Prices Compared

What eloralintide costs in November 2026: 10 mg research vials list from $63.75 to $168 across US vendors, median $109.99. Prices checked on each seller’s own page.